ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

recombinant FVIIa

Also written as “activated recombinant human factor VII”, “eptacog alfa (activated)” and “Coagulation Factor VIIa (Recombinant)”.

Its studies are mostly in Hemophilia A · Cerebral Hemorrhage · Wounds and Injuries · Fibrosis · Postpartum Hemorrhage, led by 4 companies.

Drug pageRecombinant FVIIa: every studyAll 58 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Dec 11, 200741 company-led studies, 1 open or runningNext primary completion: Aug 26, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk361 open or runningphase 4since Dec 11, 2007Jan 19, 2005Aug 26, 2027phase 4 · NCT07157423
Laboratoire français de Fractionnement et de Biotechnologiesits history only20 open or runningphase 3since Sep 9, 2015Sep 9, 2015none ahead
rEVO Biologicsits history only20 open or runningphase 3since Dec 18, 2013Oct 15, 2012none ahead
AryoGen Pharmedits history only10 open or runningphase 3since Mar 4, 2017Mar 4, 2017none ahead

Also a collaborator on its studies: LFB USA.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since Jan 19, 2005.

  1. Dec 14, 2005Phase 2 study in Cerebral HemorrhageNCT00266006 · 90 enrolled · Japan
  2. May 8, 2006Phase 3 study in Wounds and InjuriesNCT00323570 · United States
  3. Jan 24, 2007Phase 2 study in Cerebral HemorrhageNCT00426803 · 400 enrolled · Australia, Austria, Belgium and more
  4. Jun 13, 2007Phase 2 study in Hemophilia ANCT00486278 · 51 enrolled · United States, Argentina, Brazil and more
  5. Dec 11, 2007Phase 4 study in Congenital Bleeding DisorderNCT00571584 · 24 enrolled · France, Hungary, Israel and more
  6. Jul 8, 2011Phase 3 study in Congenital Bleeding DisorderNCT01392547 · 72 enrolled · United States, Austria, Brazil and more
  7. Mar 21, 20127 phase 1 studiesNCT01562457, NCT01561950, NCT01561937 and 4 more
  8. Mar 21, 2012Phase 4 study in Congenital Bleeding DisorderNCT01561391 · 36 enrolled · United States
  9. Mar 21, 20128 phase 2 studiesNCT01561352, NCT01563458, NCT01562821 and 5 more
  10. Mar 22, 2012Phase 3 study in Acquired Bleeding DisorderNCT01562574 · 82 enrolled · Australia
  11. May 14, 20122 phase 2 studiesNCT01601613, NCT01601457
  12. Sep 13, 2013Phase 1 study in Hemophilia ANCT01949792 · 6 enrolled · Spain
  13. Jan 28, 2014Phase 1 study in Hemophilia ANCT02084810
  14. Aug 19, 2025Phase 4 study in Postpartum HemorrhageNCT07157423 · 64 planned · India

Ahead

  1. Aug 26, 2027Primary completion: phase 4 study in Postpartum HemorrhageNCT07157423

TargetBeta

F7 →read by rule
“A recombinant form of the vitamin K-dependent glycoprotein and coagulation factor VIIa (FVIIa), that can be used for the treatment of bleeding episodes and perioperative management in patients with hemophilia, congenital Factor VII (FVII) deficiency, and Glanzmann's thrombasthenia”NCIt, by rule

Studies

All 36 Novo Nordisk leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07157423Postpartum Hemorrhage · India4RecruitingAug 26, 202764
NCT02084810Hemophilia A1WithdrawnJul 20140
NCT01949792Hemophilia A · Spain1CompletedNov 20136
NCT01601457Wounds and Injuries · United Kingdom2CompletedApr 200448
NCT01601613Dengue · Malaysia, Philippines, Thailand2CompletedNov 200228
NCT01566786Cerebral Hemorrhage · Australia, Denmark, Finland and more2CompletedOct 200248
NCT01564563Acquired Bleeding Disorder · United States2TerminatedOct 27, 200311
NCT01563523Wounds and Injuries · Australia, Austria, Canada and more2CompletedOct 2003283
NCT01563471Congenital Bleeding Disorder · France1CompletedJul 200239
NCT01563445Cerebral Hemorrhage · United States2CompletedMar 200340
NCT01563458Acquired Bleeding Disorder · Australia, Canada, France and more2CompletedAug 2003208
NCT01562821Fibrosis · China, Taiwan, Thailand2CompletedDec 2002235
NCT01562587Hemophilia A · Germany, Greece, Italy and more1CompletedMay 200318
NCT01562574Acquired Bleeding Disorder · Australia3CompletedAug 200482
NCT01562158Acquired Bleeding Disorder · United States, Australia, Austria and more2CompletedOct 2003100
NCT01562457Hemophilia A · France, Germany, Israel1CompletedApr 200630
NCT01561950Haemostasis · United States1TerminatedJan 200991
NCT01561937Haemostasis · United States1CompletedJul 2008127
NCT01561924Congenital Bleeding Disorder · United States, Denmark, France and more1CompletedMay 200617
NCT01561417Thrombasthenia · France1CompletedSep 200628
NCT01561391Congenital Bleeding Disorder · United States4CompletedMay 200436
NCT01561352Cystitis, Hemorrhagic · United States2CompletedNov 20037
NCT01392547Congenital Bleeding Disorder · United States, Austria, Brazil and more3CompletedAug 201272
NCT00571584Congenital Bleeding Disorder · France, Hungary, Israel and more4CompletedMar 200424
NCT00486278Hemophilia A · United States, Argentina, Brazil and more2CompletedJun 201051
NCT00426803Cerebral Hemorrhage · Australia, Austria, Belgium and more2CompletedJun 2004400
NCT00323570Wounds and Injuries · United States3WithdrawnJun 20070
NCT00266006Cerebral Hemorrhage · Japan2CompletedApr 200790
NCT00184548Wounds and Injuries · United States, Brazil, Czech Republic and more3TerminatedSep 2008554
NCT00154492Fibrosis · Austria, Czech Republic, Denmark and more2CompletedAug 2006265
NCT00154427Acquired Bleeding Disorder · United States, Argentina, Brazil and more2TerminatedNov 2007172
NCT00127283Cerebral Hemorrhage · United States, Australia, Austria and more3CompletedJan 2007829
NCT00123591Wounds and Injuries · Canada, Finland, Germany and more2CompletedMay 200696
NCT00108758Congenital Bleeding Disorder · United States, Argentina, Brazil and more2CompletedNov 200523
NCT00104455Congenital Bleeding Disorder · United States1CompletedNov 200464
NCT00102037Acquired Bleeding Disorder · United States2CompletedFeb 200650

How it is read

Names in the registry

  • “activated recombinant human factor VII”, 32 entries
  • “eptacog alfa (activated)”, 12 entries
  • “Coagulation Factor VIIa (Recombinant)”, 3 entries
  • “Eptacog alfa (NovoSeven)”, 1 entry
  • “Eptacog alfa, biosimilar”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.